Pegozafermin is being studied to see if it helps lower high triglyceride levels in the blood. Triglycerides are a type of fat, and having too many (500 to 2000 mg/dL) can be harmful. This study will last for 26 weeks, and participants will be asked to keep their medicine, eating, and exercise habits the same.

Eligibility: You must be at least 22 years old and already on treatment for managing cholesterol-related heart risks. You cannot join if you have certain infections like hepatitis or HIV, or if you have uncontrolled diabetes or recent gallstone problems.

Key Points:

• The study lasts for 26 weeks with no changes to your current lifestyle or medication routine.
• Participants need to have stable cholesterol treatment before starting.
• Risks include being ineligible if you have certain health conditions like type 1 diabetes or recent pancreatitis.

In summary, this study looks at whether Pegozafermin can safely lower high triglyceride levels over 26 weeks. If you meet the criteria and maintain stable health habits, you could be eligible to participate.